Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rhelion Life SciencesSTU:4YX0 EV-to-FCF is -2.57 as of Aug. 07, 2026. The stock has 3 warning signs investors should review. Among 569 Drug Manufacturers companies, Rhelion Life Sciences ranks worse than 175746.75% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Rhelion Life Sciences's Enterprise Value is €5.86 Mil.
Rhelion Life Sciences's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €-2.28 Mil. Therefore, Rhelion Life Sciences's EV-to-FCF for today is -2.57.
The historical rank and industry rank for Rhelion Life Sciences's EV-to-FCF or its related term are showing as below:
STU:4YX0'
s EV-to-FCF Range Over the Past 10 Years
Min: -18.8 Med: -2.46 Max: 0.78
Current: -2.6
During the past 8 years, the highest EV-to-FCF of Rhelion Life Sciences was 0.78. The lowest was -18.80. And the median was -2.46.
STU:4YX0's EV-to-FCF is ranked worse than 100% of 569
companies
in the Drug Manufacturers industry
Industry Median: 21.6
vs STU:4YX0: -2.60
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Rhelion Life Sciences (STU:4YX0) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Rhelion Life Sciences's PE Ratio (TTM) for today is calculated as:
Rhelion Life Sciences's share price for today is €0.007.
Rhelion Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.003.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Rhelion Life Sciences's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rhelion Life Sciences EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Rhelion Life Sciences's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Rhelion Life Sciences's EV-to-FCF falls into.
Rhelion Life Sciences's current Enterprise Value is €5.86 Mil.
Rhelion Life Sciences's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.28 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rhelion Life Sciences (STU:4YX0) has a EV-to-FCF of -2.57 as of Aug. 07, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Rhelion Life Sciences and its competitors. According to the industry distribution chart, Rhelion Life Sciences ranks #999999 out of 569 companies in the Drug Manufacturers industry.
Is Rhelion Life Sciences' EV-to-FCF too high?
Rhelion Life Sciences' current EV-to-FCF is -2.57. Based on the distribution chart, Rhelion Life Sciences ranks #999999 out of 569 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Rhelion Life Sciences' EV-to-FCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Rhelion Life Sciences ranks #999999 out of 569 companies for EV-to-FCF. This places Rhelion Life Sciences in the lower half of its industry. The industry median EV-to-FCF is 21.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 21.60, based on 569 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Rhelion Life Sciences and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 21.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rhelion Life Sciences's current EV-to-FCF is -2.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rhelion Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Rhelion Life Sciences (STU:4YX0) is currently considered Possible Value Trap. The stock's GF Value™ is €0.01, compared to a current price of €0.01 — trading 30% below its estimated fair value. The current EV-to-FCF is -2.57. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Rhelion Life Sciences (STU:4YX0), the current EV-to-FCF is -2.57 as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Red Light Holland Corp is engaged in the production, growth, and sale of functional mushrooms and mushroom home grow kits in North America and Europe, and a premium brand of psilocybin truffles to the legal, recreational market within the Netherlands. Its products include Microdosing Kit and Merch. Its revenue is comprised of sales of wholesale truffles, cannabis seeds, and other cannabis products and sales of microdose packs.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:4YX0 has been successfully added to your 
